|Bid||28.37 x 800|
|Ask||28.43 x 800|
|Day's range||28.25 - 29.14|
|52-week range||16.85 - 45.04|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2020 - 09 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||52.50|
A low-key week for the biotech sector, with a few pipeline and regulatory updates.
Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.
Investors need to pay close attention to Apellis Pharmaceuticals (APLS) stock based on the movements in the options market lately.